文献速递乳房整形与再造显微修复重建

BRCA1/2阳性患者预防性乳房切除与自体皮瓣重建的成本效果

Cost Effectiveness of Prophylactic Mastectomy and Autologous Flap Reconstruction in BRCA1/2 -Positive Patients.
PubMed 文献 · Plast Reconstr Surg · 2025-03-14

本研究用10万例患者的马尔可夫链蒙特卡洛模拟,比较BRCA1/2突变女性在25岁起年度筛查与30、35或40岁行预防性乳房切除联合自体皮瓣重建的成本效果;所有自体皮瓣的增量成本效果比均低于5万美元支付意愿阈值,提示具有成本效果,DIEP皮瓣最低;预防性手术对BRCA1患者比BRCA2患者更具成本效果。

要点

  • 所有自体皮瓣的增量成本效果比均低于5万美元支付意愿阈值,提示具有成本效果。
  • DIEP皮瓣的增量成本效果比最低,游离横腹直肌肌皮瓣与DIEP皮瓣为最具成本效果的技术。
  • 预防性手术对BRCA1患者比BRCA2患者更具成本效果。

核心结论

  • 在30、35或40岁行预防性乳房切除联合自体皮瓣重建,对BRCA1/2突变女性是优于乳腺癌监测与疾病治疗的成本效果替代方案。
  • DIEP皮瓣与游离横腹直肌肌皮瓣为最具成本效果的技术。
  • 预防性手术对BRCA1患者比BRCA2患者更具成本效果。

研究设计与样本

  • 研究采用马尔可夫链蒙特卡洛模拟,纳入100,000例患者。
  • 所有模型假设基线为25岁携带BRCA1或BRCA2突变的女性。
  • 标准诊疗模型为每年筛查(磁共振成像加乳腺X线摄影)至75岁,阳性筛查者行乳房切除后以组织扩张器和假体行两期乳房重建。
  • 对照方案为在30、35或40岁行预防性乳房切除联合自体皮瓣重建(游离横腹直肌肌皮瓣、臀肌皮瓣、大腿皮瓣或腹壁下动脉穿支(DIEP)皮瓣)。
  • 评估参数包括成本、生活质量与增量成本效果比。

主要发现

  • 所有自体皮瓣的增量成本效果比均低于5万美元支付意愿阈值,提示具有成本效果,其中DIEP皮瓣最低。
  • 预防性乳房切除联合自体重建对BRCA1患者比BRCA2患者更具成本效果。
  • 敏感性分析显示,预防性手术达到成本效果最早为DIEP皮瓣(50至63岁),最晚为臀肌皮瓣(58至73岁)。

关键数值与推荐

  • 支付意愿阈值为50,000美元。
  • 所有自体皮瓣的增量成本效果比均低于50,000美元。
  • 敏感性分析中DIEP皮瓣在50至63岁达到成本效果,臀肌皮瓣在58至73岁达到成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients diagnosed with having the breast cancer gene ( BRCA1 or BRCA2 ) face a critical choice between prophylactic mastectomy and serial surveillance screening. This study aimed to evaluate the cost effectiveness of prophylactic mastectomy with autologous reconstruction compared with surveillance strategies for this patient population. METHODS: Markov chain Monte Carlo simulations comprising 100,000 patients were used. All models assumed a baseline of women aged 25 years with BRCA1 or BRCA2 mutations. In the standard-of-care model, patients underwent annual screening (magnetic resonance imaging plus mammography) until age 75 years. Positive screenings led to mastectomy followed by 2-stage breast reconstruction using tissue expanders and implants. This approach was compared with prophylactic mastectomy with autologous flap reconstruction (free transverse rectus abdominis myocutaneous, gluteal, thigh, or deep inferior epigastric perforator [DIEP] flaps) at ages 30, 35, or 40 years. Evaluation parameters included cost, quality of life, and incremental cost-effectiveness ratios. RESULTS: The incremental cost-effectiveness ratios of all autologous flaps were below the willingness-to-pay threshold of $50,000, suggesting cost effectiveness, with DIEP flaps being the lowest. Prophylactic mastectomy with autologous reconstruction was more cost effective for BRCA1 patients than for BRCA2 patients, and sensitivity analysis revealed that prophylaxis became cost effective earliest for DIEP flaps (ages 50 to 63 years) and latest for gluteal flaps (ages 58 to 73 years). CONCLUSIONS: Prophylactic mastectomy with autologous reconstruction performed at ages 30, 35 or 40 years, was found to be a cost-effective alternative to breast cancer surveillance and disease treatment in women with BRCA1/2 mutations. DIEP and free transverse rectus abdominis myocutaneous flaps were the most cost-effective techniques, and prophylaxis was more cost effective in BRCA1 patients than in BRCA2 patients.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Smith RW, Subramaniam S, Arora JS, et al. Cost Effectiveness of Prophylactic Mastectomy and Autologous Flap Reconstruction in BRCA1/2 -Positive Patients. Plast Reconstr Surg. 2025. PMID: 40100117. doi:10.1097/PRS.0000000000012094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。